MaxCyte, Inc. Cost of Revenue
MaxCyte, Inc. (MXCT) reported Cost of Revenue of $943.80 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2021-11-10
- MaxCyte, Inc. cost of revenue for the quarter ending 2021-09-30 was $943.80K, a 28.44% increase year-over-year.
- MaxCyte, Inc. cost of revenue for the quarter ending 2021-06-30 was $784.50K, a 68.24% increase year-over-year.
- MaxCyte, Inc. cost of revenue for the quarter ending 2020-09-30 was $734.80K.
- MaxCyte, Inc. cost of revenue for the quarter ending 2020-06-30 was $466.30K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month |
|---|---|---|---|
| 2021-09-30 | $943.80K 10-Q · filed 2021-11-10 | $1.73M derived: sum of 2 quarters · filed 2021-11-10 | $2.42M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $784.50K 10-Q · filed 2021-09-13 | $1.48M 10-Q · filed 2021-09-13 | |
| 2020-09-30 | $734.80K 10-Q · filed 2021-11-10 | $1.20M derived: sum of 2 quarters · filed 2021-11-10 | $1.86M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $466.30K 10-Q · filed 2021-09-13 | $1.13M 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |